Private Equity
Andrea Alms Video: Money In Motion 130 - Hypertrophic Cardiomyopathy Therapeutics Market
October 2024 - Private Equity
TRANSCRIPT: Hello, my name is Andrea Alms. I am technology investor and financial manager. And this is your money emotion. What is it? Hypertrophic cardiomyopathy therapeutics means treatment for heart muscle that is abnormally thick or hypertrophy. The thickening heart muscle makes the heart ineffective in pumping blood. The major drug types are antiarrhythmic agents, anticoagulant. Beta adrenergic blocking drugs, calcium channel blockers, and others.
Devices include defibrillators, pacemakers, and other devices. One type of hypertrophy is called left ventricular hypertrophy. This. How common is it? LV age affects nearly 10 to 20% of the population globally. Nearly 1 in 5 people. You may have increased risk of LV if you have high blood pressure, obesity, elderly or black. A business research company, the market was 1.3 billion in 2023 and forecast to grow to 1.48 billion in 2028 at a compound average growth rate of 2.6%, as Stratosphere research to market was 1.3 billion in 2020, and forecast to grow to 1.46 billion in 2026 at a compound average growth rate of 2.4%.
At Research and Insights, the market was 1.3 billion in 2023 and forecast to grow to 1.74 billion in 2032, at a compound average growth rate of 3.2%. Averaging the averages, the market is 1.3 billion, with growth rate of 2.7. Surprisingly, a relatively small market when 1 in 5 people have this condition. Let's explore this on the next episode.
Thank you. This is your money. Your money in motion.